Literature DB >> 9280078

Prevalence, management and outcome of early adenocarcinoma (pT1) of the esophago-gastric junction. Comparison between early cancer in Barrett's esophagus (type I) and early cancer of the cardia (type II).

A Ruol1, S Merigliano, N Baldan, S Santi, G F Petrin, L Bonavina, E Ancona, A Peracchia.   

Abstract

The study compares, in true adenocarcinoma of the cardia and in adenocarcinoma in Barrett's esophagus, the prevalence of early cancers and their outcome in those patients suitable for resection surgery. From 1980 to 1993, 26 of 350 (7.4%) resected adenocarcinomas of the esophago-gastric junction were pathologically staged as early cancer or pT1. The prevalence of early cancer was 3.7% (11/294) for true cancer of the cardia and 27% (15/56) for cancer in Barrett's esophagus (P < 0.001). Ten of the 15 latter cancers were diagnosed during endoscopic surveillance for benign Barrett's esophagus. Among early cancers, there were four mucosal and 22 submucosal tumours; of the latter, eight had lymph node metastasis and seven neoplastic permeation of lympho-hematic vessels. The most frequently used surgical procedure was esophago-gastric resection and gastric pull-up. Postoperative morbidity was 15.4%, and hospital mortality 3.8%. Excluding postoperative deaths, the overall 5-year survival rate was 79% for early cancer of the cardia and 83% for early cancer in Barrett's esophagus (log rank test = 0.0214, P = 0.88). Overall, the survival rate was 100% in the absence of lymph node metastasis and 43% in the presence of node metastasis (log rank test = 15.811, P = 0.0001). Only one of five patients with both node metastasis and vessel infiltration survived longer than 5 years. In conclusion, the prevalence of early cancer was significantly greater for cancer in Barrett's esophagus than for true cancer of the cardia. Prognosis of the two types of tumour after resection surgery was the same and depended on lymph node status and neoplastic permeation of lympho-hematic vessels.

Entities:  

Mesh:

Year:  1997        PMID: 9280078     DOI: 10.1093/dote/10.3.190

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  7 in total

1.  Early Barrett's carcinoma: the depth of infiltration of the tumour correlates with the degree of differentiation, the incidence of lymphatic vessel and venous invasion.

Authors:  Barbara Zemler; Andrea May; Christian Ell; Manfred Stolte
Journal:  Virchows Arch       Date:  2010-05-07       Impact factor: 4.064

Review 2.  Current Strategies in the management of Barrett's esophagus.

Authors:  Kenneth K Wang
Journal:  Curr Gastroenterol Rep       Date:  2005-06

3.  A Model Based on Pathologic Features of Superficial Esophageal Adenocarcinoma Complements Clinical Node Staging in Determining Risk of Metastasis to Lymph Nodes.

Authors:  Jon M Davison; Michael S Landau; James D Luketich; Kevin M McGrath; Tyler J Foxwell; Douglas P Landsittel; Michael K Gibson; Katie S Nason
Journal:  Clin Gastroenterol Hepatol       Date:  2015-10-26       Impact factor: 11.382

Review 4.  The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review.

Authors:  Kerry B Dunbar; Stuart Jon Spechler
Journal:  Am J Gastroenterol       Date:  2012-06       Impact factor: 10.864

5.  Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma.

Authors:  Rami J Badreddine; Ganapathy A Prasad; Jason T Lewis; Lori S Lutzke; Lynn S Borkenhagen; Kelly T Dunagan; Kenneth K Wang
Journal:  Clin Gastroenterol Hepatol       Date:  2009-11-27       Impact factor: 11.382

Review 6.  Endoscopic mucosal resection in the upper gastrointestinal tract.

Authors:  Anis Ahmadi; Peter Draganov
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

7.  Tumor budding is associated with an increased risk of lymph node metastasis and poor prognosis in superficial esophageal adenocarcinoma.

Authors:  Michael S Landau; Steven M Hastings; Tyler J Foxwell; James D Luketich; Katie S Nason; Jon M Davison
Journal:  Mod Pathol       Date:  2014-04-25       Impact factor: 7.842

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.